Global contract development and manufacturing organisation (CDMO), Recipharm, has acquired GenIbet in a deal designed to strengthen Recipharm’s presence in the biologics market.
Genlbet is a Portuguese CDMO specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors RNA and microbiome.
The company currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes. Through its relationship with not-for-profit research organisation Ibet, the CDMO offers deep scientific expertise and novel solutions where no established production route exists.
The acquisition will see GenIbet form part of Recipharm’s strategy to establish itself in the biologics market, with a particular focus on drug substance manufacturing of novel advanced therapy medicinal products (ATMPs).
Marc Funk, chief executive officer at Recipharm, said: “We’re delighted to welcome GenIbet and its talented team of experts. GenIbet is a leading player in its field so we’re proud to bring it under the Recipharm umbrella and tap into its broad offering in novel modalities and incredible scientific expertise.
This acquisition is an important step for us in growing our biologics business. We look forward to working closely with the GenIbet team, building links across the wider Recipharm organisation to make this business a huge success.”
Raquel Fortunato, CEO at GenIbet, added: “We’ve enjoyed a great deal of success at GenIbet, and now is a fantastic time to be joining with Recipharm to share our expertise and broad service offer.
I’m thrilled that GenIbet will play an important role in Recipharm’s Biologics-focused future. Combining our experience and expertise with Recipharm’s capabilities and market reach, will make a significant difference for customers on an international scale.”